EuroBiotix CIC is a community interest company (CIC) that was incorporated in November 2014. The company is limited by shares and is registered under the company number of SC490561.) EuroBiotix CIC was formed to fill an unmet need for safe access to a medical treatment called Faecal Microbiota Transplantation (FMT). To meet this need, EuroBiotix is developing a range of market leading services and products that will catalyse research into the gut microbiome, and dramatically reduce the costs and hassle associated with performing FMT.
The founders chose to incorporate as a CIC in order to serve their vision as being a company with a primary aim to support patients suffering from microbiome mediated conditions. The requirements of an asset lock and community purpose by the CIC regulator ensure that this social mission is protected.
A well-balanced management team with a wide variety of skills leads EuroBiotix CIC. The board of directors includes a chartered engineer with four decades of project management and senior management experience, and a non-executive acting as chairman who has worked extensively in the UK public service and not–for–profit sectors, across local government and health. EuroBiotix is supported by a high profile independent advisory board comprised of six leading clinicians and scientists with expertise and experience in gut health, faecal transplantation, and microbiology.